Circular RNA Networks in Hepatocytes: Mechanisms, Clinical Implications, and Emerging Therapeutic Targets

Abstract

Circular RNAs (circRNAs) are a class of non-coding RNAs increasingly recognized as pivotal regulators within hepatocytes, influencing gene expression, cellular homeostasis, and disease progression. This article reviews recent advances in the understanding of circRNA networks in hepatocytes, elucidating their roles in liver physiology and pathology, including hepatocellular carcinoma, nonalcoholic fatty liver disease, and viral hepatitis. We discuss the epidemiology, molecular mechanisms, risk factors, clinical features, diagnostic approaches, therapeutic strategies, and future directions for leveraging circRNA biology in hepatology, with a focus on translational and clinical relevance for healthcare professionals.

Introduction

Hepatocytes, as the principal functional cells of the liver, are central to metabolic regulation, detoxification, and immune responses. Recent advances in RNA sequencing technologies have uncovered a diverse and dynamic landscape of non-coding RNAs in hepatocytes, with circular RNAs (circRNAs) emerging as critical regulatory molecules. Unlike linear RNAs, circRNAs form covalently closed loops, rendering them resistant to exonuclease-mediated degradation and uniquely suited for stable gene regulation. Their ability to function as microRNA sponges, interact with RNA-binding proteins, and modulate transcription underscores their importance in liver biology and disease. Understanding circRNA networks in hepatocytes is increasingly relevant for clinicians, given the mounting evidence linking circRNA dysregulation to liver disease pathogenesis and therapeutic response.

Epidemiology / Disease Burden

The global burden of liver diseases is substantial, with chronic liver conditions such as hepatitis B and C, nonalcoholic fatty liver disease (NAFLD), and hepatocellular carcinoma (HCC) accounting for over two million deaths annually. While circRNAs themselves are not directly tracked epidemiologically, high-throughput transcriptome analyses have revealed widespread dysregulation of circRNA expression in liver diseases. For example, alterations in specific circRNA profiles have been consistently observed in the sera and liver tissues of patients with HCC and NAFLD. The growing recognition of circRNAs as biomarkers and therapeutic targets reflects their potential impact on disease burden and patient outcomes.

Pathophysiology

CircRNAs modulate hepatocyte function through diverse mechanisms. Many act as competitive endogenous RNAs, sequestering microRNAs (miRNAs) and thereby influencing the expression of target messenger RNAs (mRNAs). Others interact with RNA-binding proteins, modulating their activity or localization. In hepatocytes, circRNAs such as circMTO1 and circHIPK3 have been shown to regulate cell proliferation, apoptosis, and metabolic pathways. Dysregulation of circRNA networks contributes to oncogenesis, steatosis, inflammation, and fibrosis. For instance, overexpression of circRNA_100338 promotes metastasis in HCC by activating the Wnt/β-catenin pathway, while circRNA_0046366 suppresses hepatocyte lipid deposition by sponging miR-34a.

Risk Factors

The dysregulation of circRNAs in hepatocytes is influenced by both intrinsic and extrinsic factors. Chronic viral hepatitis (HBV, HCV), excessive alcohol intake, metabolic syndrome, and exposure to hepatotoxins are associated with altered circRNA expression profiles. Genetic polymorphisms affecting circRNA biogenesis or degradation may also predispose individuals to aberrant circRNA-mediated signaling. Additionally, age, sex, and comorbidities such as diabetes and obesity modulate circRNA dynamics, impacting susceptibility to liver diseases.

Clinical Features

CircRNA dysregulation in hepatocytes correlates with diverse clinical manifestations depending on the underlying liver pathology. In HCC, patients often present with symptoms of liver dysfunction, jaundice, abdominal pain, and cachexia, with specific circRNAs (such as circZKSCAN1) associated with tumor aggressiveness and recurrence. In NAFLD and nonalcoholic steatohepatitis (NASH), altered circRNA profiles are linked to hepatic steatosis, inflammation, and progression to fibrosis. Emerging data suggest that circulating circRNAs may reflect disease activity and correlate with clinical features, offering promise as non-invasive biomarkers.

Diagnosis

Conventional diagnostic approaches in hepatology rely on clinical assessment, imaging modalities, and histopathological evaluation. However, the stability and tissue specificity of circRNAs make them attractive as novel diagnostic biomarkers. Quantitative real-time PCR, RNA sequencing, and microarray platforms are employed to detect and profile circRNAs in liver tissue and biofluids. Recent studies highlight the diagnostic utility of serum circRNAs in distinguishing HCC from benign liver lesions and in monitoring disease progression in NAFLD. Integration of circRNA-based assays into clinical workflows could enhance diagnostic accuracy and facilitate personalized medicine.

Treatment & Management

Current treatment strategies for liver diseases are dictated by the underlying etiology and stage. While antiviral agents, lifestyle modification, and surgical interventions remain mainstays, there is growing interest in targeting circRNA networks for therapeutic gain. Preclinical studies demonstrate that modulating circRNA expression using antisense oligonucleotides or small molecules can influence hepatocyte proliferation, apoptosis, and fibrosis. For instance, silencing oncogenic circRNAs such as circRNA_104075 has been shown to inhibit HCC growth in animal models. However, translating these approaches into clinical practice requires further validation and optimization.

Recent Advances / Emerging Therapies

Major advances in circRNA research have been propelled by high-throughput sequencing and novel bioinformatics tools enabling comprehensive circRNA profiling. Therapeutic strategies targeting circRNAs are evolving, with RNA interference, CRISPR/Cas-mediated editing, and circRNA mimics under investigation. Nanoparticle-based delivery systems are being optimized for hepatic targeting. Additionally, circRNAs are being explored as adjuncts to existing therapies, enhancing chemosensitivity or immunomodulation in HCC. Clinical trials evaluating the safety and efficacy of circRNA-targeted interventions are anticipated in the near future, marking a new era in hepatology therapeutics.

Guideline Recommendations

While formal clinical guidelines incorporating circRNA biomarkers or therapeutics in hepatology are not yet available, multiple consensus statements and expert reviews underscore the need for standardized protocols in circRNA detection and validation. Professional societies recommend rigorous methodological approaches, independent cohort validation, and integration with conventional clinical parameters. As the evidence base expands, future guidelines are expected to define the clinical roles of circRNAs in diagnosis, prognosis, and therapy selection for liver diseases.

Conclusion

The expanding landscape of circular RNA networks in hepatocytes represents a paradigm shift in our understanding of liver biology and disease. CircRNAs orchestrate complex regulatory circuits with profound implications for hepatocyte function, disease pathogenesis, and therapeutic intervention. Continued research into circRNA mechanisms, clinical associations, and translational applications offers significant promise for improving the diagnosis, management, and outcomes of patients with liver diseases. For clinicians and researchers, a nuanced appreciation of circRNA biology is essential for harnessing these molecules as next-generation biomarkers and therapeutic targets in hepatology.